Attendee search 

Lumira Capital is a Venture Capital firm that changed its name from MDS Capital In 2007 and have been investing in companies since 1989. The firm is based in Toronto will additional offices in Boston and Montreal. The firm currently manages 2 funds for a total of approximately $180 million in assets under management. The firm’s Lumira Capital II fund currently hold approximately $115 million in assets and is looking to invest in companies across North America. The firms Merck Lumira Biosciences fund formed via a partnership with Merck Serano, currently holds around $65 million in assets and is looking for early stage opportunities in companies located in or looking to move to Quebec. The firm typically makes initial investments ranging from $2-$5 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm plans to make 4-6 investments over the next 6-9 months.

NuvOx Pharma is developing a series of biologics that increase tissue oxygenation. The company's first market will be in oncology, where increased tumor oxygenation increases the response of tumors to radiation therapy. The company recently started a Phase 1b clinical trial in Glioblastoma Multiforme, and is raising a $2.5 million Series A to complete this trial. Afterwards it will seek partners for a Phase 2b in Glioblastoma, and Phase 1b trials in lung cancer and other oncology indications. After growing to a critical mass in oncology, the company will seek to become standard treatment to increase tissue oxygenation for patients suffering from heart attack, stroke, hemorrhaggic shock, and traumatic brain injury.